Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
TauRx is preparing to submit its oral Alzheimer’s treatment hydromethylthionine mesylate (HMTM) for approval to the US Food and Drug Administration (FDA) in the first quarter of next year (that is, Q1 2026).